FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311630005> ?p ?o ?g. }

• W4311630005 abstract "Gliflozins altering the sodium-glucose transport protein 2 (SGLT2) in the nephron, represent alone or in combination a promising treatment option for patients with type II diabetes mellitus. In addition to glucose control, these drugs provide benefits including reduced risk of long-term cardiovascular (CV) and renal complications. Several trials evaluated gliflozins in patients with various degrees of cardiac dysfunction with heterogeneous results.We aimed to perform a comprehensive analysis of the effect of gliflozins on CV outcomes.Systematic searches of electronic databases were conducted until September 2022. Multiple treatment network meta-analysis was performed in R. Random-effects model was used to combine risk estimates across trials calculating risk ratio (RR) with 95% confidence intervals as summary statistics. The primary endpoint of interest was the rate of heart failure-related hospitalization (HHF) and the composite of HHF with CV mortality (HHF + CVD). Secondary outcomes included major adverse cardiac events (MACE), CV- and overall mortality, myocardial infarction (MI), and stroke.Twenty-nine studies randomizing 88,418 patients were identified. Gliflozins reduced the risk of HHF (RR: 0.72 [0.69; 0.76]) and HHF + CVD (RR: 0.78 [0.75; 0.82]). The risk of MACE and its component also improved significantly except for stroke. The network analyses did not explore major differences among the individual substances. The only exception was sotagliflozin which appeared to be more effective regarding HHF + CVD, stroke, and MI compared to ertugliflozin, in HHF + CVD and stroke compared to dapagliflozin, and in stroke endpoint compared to empagliflozin.Our meta-analysis supports a group effect of gliflozins beneficial in a wide spectrum of patients with a risk of heart failure (HF) development. In addition to the improvement of HF-related outcomes, the risk of major adverse events is also reduced with SGLT2 inhibition.[www.ClinicalTrials.gov], identifier [CRD42022358078]." @default.
• W4311630005 created "2022-12-27" @default.
• W4311630005 creator A5002198505 @default.
• W4311630005 creator A5010789332 @default.
• W4311630005 creator A5046103344 @default.
• W4311630005 creator A5046660116 @default.
• W4311630005 creator A5073075473 @default.
• W4311630005 creator A5081040561 @default.
• W4311630005 creator A5090404434 @default.
• W4311630005 date "2022-12-05" @default.
• W4311630005 modified "2023-10-18" @default.
• W4311630005 title "Cardiovascular outcomes in patients treated with sodium-glucose transport protein 2 inhibitors, a network meta-analysis of randomized trials" @default.
• W4311630005 cites W1617328014 @default.
• W4311630005 cites W2091808438 @default.
• W4311630005 cites W2126930838 @default.
• W4311630005 cites W2146264128 @default.
• W4311630005 cites W2158229692 @default.
• W4311630005 cites W2381622136 @default.
• W4311630005 cites W2618377980 @default.
• W4311630005 cites W2626446274 @default.
• W4311630005 cites W2809153459 @default.
• W4311630005 cites W2809590939 @default.
• W4311630005 cites W2884466498 @default.
• W4311630005 cites W2899764361 @default.
• W4311630005 cites W2900413769 @default.
• W4311630005 cites W2939222610 @default.
• W4311630005 cites W2974260792 @default.
• W4311630005 cites W2974621372 @default.
• W4311630005 cites W2989060738 @default.
• W4311630005 cites W2989579906 @default.
• W4311630005 cites W3000647500 @default.
• W4311630005 cites W3015179476 @default.
• W4311630005 cites W3018301168 @default.
• W4311630005 cites W3041394830 @default.
• W4311630005 cites W3043676355 @default.
• W4311630005 cites W3047208451 @default.
• W4311630005 cites W3081830235 @default.
• W4311630005 cites W3082758064 @default.
• W4311630005 cites W3084081810 @default.
• W4311630005 cites W3088173406 @default.
• W4311630005 cites W3089283105 @default.
• W4311630005 cites W3098234982 @default.
• W4311630005 cites W3100542962 @default.
• W4311630005 cites W3101044784 @default.
• W4311630005 cites W3102766101 @default.
• W4311630005 cites W3164477560 @default.
• W4311630005 cites W3184824673 @default.
• W4311630005 cites W3189855140 @default.
• W4311630005 cites W3193297191 @default.
• W4311630005 cites W3193598686 @default.
• W4311630005 cites W3210475044 @default.
• W4311630005 cites W4211210537 @default.
• W4311630005 cites W4213368576 @default.
• W4311630005 cites W4214512384 @default.
• W4311630005 cites W4214940159 @default.
• W4311630005 cites W4220837239 @default.
• W4311630005 cites W4281382249 @default.
• W4311630005 cites W4293354639 @default.
• W4311630005 cites W4293779734 @default.
• W4311630005 doi "https://doi.org/10.3389/fcvm.2022.1041200" @default.
• W4311630005 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36545024" @default.
• W4311630005 hasPublicationYear "2022" @default.
• W4311630005 type Work @default.
• W4311630005 citedByCount "2" @default.
• W4311630005 countsByYear W43116300052023 @default.
• W4311630005 crossrefType "journal-article" @default.
• W4311630005 hasAuthorship W4311630005A5002198505 @default.
• W4311630005 hasAuthorship W4311630005A5010789332 @default.
• W4311630005 hasAuthorship W4311630005A5046103344 @default.
• W4311630005 hasAuthorship W4311630005A5046660116 @default.
• W4311630005 hasAuthorship W4311630005A5073075473 @default.
• W4311630005 hasAuthorship W4311630005A5081040561 @default.
• W4311630005 hasAuthorship W4311630005A5090404434 @default.
• W4311630005 hasBestOaLocation W43116300051 @default.
• W4311630005 hasConcept C126322002 @default.
• W4311630005 hasConcept C127413603 @default.
• W4311630005 hasConcept C134018914 @default.
• W4311630005 hasConcept C164705383 @default.
• W4311630005 hasConcept C168563851 @default.
• W4311630005 hasConcept C203092338 @default.
• W4311630005 hasConcept C207103383 @default.
• W4311630005 hasConcept C2775887513 @default.
• W4311630005 hasConcept C2777422806 @default.
• W4311630005 hasConcept C2777451236 @default.
• W4311630005 hasConcept C2780645631 @default.
• W4311630005 hasConcept C2780739214 @default.
• W4311630005 hasConcept C2910068830 @default.
• W4311630005 hasConcept C44249647 @default.
• W4311630005 hasConcept C45393284 @default.
• W4311630005 hasConcept C500558357 @default.
• W4311630005 hasConcept C555293320 @default.
• W4311630005 hasConcept C71924100 @default.
• W4311630005 hasConcept C78519656 @default.
• W4311630005 hasConcept C82789193 @default.
• W4311630005 hasConcept C95190672 @default.
• W4311630005 hasConceptScore W4311630005C126322002 @default.
• W4311630005 hasConceptScore W4311630005C127413603 @default.
• W4311630005 hasConceptScore W4311630005C134018914 @default.
• W4311630005 hasConceptScore W4311630005C164705383 @default.
• W4311630005 hasConceptScore W4311630005C168563851 @default.

• next